Institutional Placement Opportunities

Continental Advisors represents small-cap public companies with strong growth potential.  CA consults with these companies and helps structure public offerings that are offered directly by the company to institutional investors.  We work with these small-cap opportunities to provide institutional investors a direct investment channel to determine if the offering is suitable for their portfolio. 
These direct offerings are normally structured as straight equity or convertible debt.  The company would also make a commitment to file a registration statement when the offering is closed so that institutional investors would have an exit strategy and the ability to mark the security according to their pricing policies.

Current opportunities

Synergy Pharmaceuticals. (Symbol: "SGYP.OB)
is a fully-reporting biopharmaceutical company based in New York that is focused on the treatment of gastro-intestinal disorders. The company has developed an in-house leading drug candidate called SP-304 for the treatment of chronic constipation and irritable bowel syndrome (IBS).  This drug is currently in a Phase IIa clinical trial in the US in chronic constipation patients.  Pre-trial results for Synergy's SP-304 have been extremely positive. 
SP-304 is similar to linaclotide, the first-in-class drug candidate from Ironwood Pharma (Symbol: "IRWD") for the same indication, however  SP-304 mimics the actual human hormone that regulates the intestinal tract while linaclotide is related to an E.coli enterotoxin called ST peptide in order to treat constipation.  Ironwood went public in February as the largest biotech IPO in history, based almost entirely on clinical results for linaclotide which is presently in Phase III trials, and now has a fully-diluted market cap of $1.71 billion.
Synergy has raised over $22 million in capital over the last two years, and is positioning SP-304 to be "best-in-class" in an emerging market that totals millions of patients worldwide that offers the potential for a blockbuster drug (> $1 billion annual sales).  The Phase IIa results for the SP-304 clinical trial should be available by September of this year.
The company will be in Europe for a EUR15 million fund raise beginning May 10th, and plans to move to the NASDAQ national market immediately after closing.
Presentation: Synergy Pharmaceuticals


Idea Fabrik Plc. (TI4:GR)
is a social networking and massively multiplayer online virtual worlds and gaming Company. Idea Fabrik is a UK Plc, listed on the Frankfurt Stock Exchange. They have gathered a huge wealth of game development talent, as well as top-class marketing specialists, in order to fulfill their goal of creating a full virtual world mirroring our own. Idea Fabrik, with it's flagship product Echoverse, aims to offer an experience that is comprehensive of the best elements of previous best-sellers such as Second Life and World of Warcraft, as well as the best of their revenue models, while going beyond both. With many different revenue streams, such as the monthly subscription fee, micro-transactions, commissions on in-game transactions and communications and in-game advertising, they are very well positioned to obtain a leading role in the growing $11 Billion per year MMORPG market.
Presentation: Idea Fabrik Plc
Company Website: Idea Fabrik online games and virtual worlds

Next Alternative, Inc. (TYN:GR)
has three unique green technologies: the Nano-Tube Battery with longer life, 10 minutes to charge, and low-cost; M-Fuel Nano-Emulsified Diesel that costs 25% less than diesel fuel, has no separation problems, and requires no alterations for diesel equipment; the Pancake Utility Motor with more torque than comparable motors at a fraction of production costs, and which is stackable. They are cash flowing and expect to be profitable during this quarter through revenues from the CNT Battery to the golf cart industry and M-Fuel emulsified diesel fuel distributed initially to the Canadian Railway System. NAI is a fully-reporting company, with circa a EUR100M market cap. The company has cash in excess of USD 2.7M on its balance sheet, no outstanding debt, and no VC or private equity investors as shareholders.
Presentation: Next Alternative Inc